Lung cancer drug alectinib put to the test in Dose-Finding trial

NCT ID NCT05713006

Recruiting now Disease control Sponsor: Instituto Nacional de Cancerologia de Mexico Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the drug alectinib in 45 Mexican patients with advanced ALK-positive non-small cell lung cancer. In the first phase, patients receive increasing doses every 21 days to measure drug levels and safety. In the second phase, the chosen dose is given to see how well it shrinks tumors. The goal is to find the best dose for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alectinib (Alecensa)
What this could lead to: If successful, this could help determine the optimal alectinib dose for ALK-positive lung cancer patients, potentially improving treatment outcomes.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply to all patients. Dose escalation may cause side effects, and the drug may not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK GENE MUTATION NON-SMALL CELL LUNG CANCER STAGE IIIB

Contacts and locations

Locations

Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
RECRUITING

Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.